365 related articles for article (PubMed ID: 26948395)
1. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
2. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
[TBL] [Abstract][Full Text] [Related]
3. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
Song W; Kwon GY; Kim JH; Lim JE; Jeon HG; Il Seo S; Jeon SS; Choi HY; Jeong BC; Lee HM
Oncotarget; 2016 Dec; 7(50):83735-83743. PubMed ID: 27863438
[TBL] [Abstract][Full Text] [Related]
5. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.
Dijkstra S; Leyten GH; Jannink SA; de Jong H; Mulders PF; van Oort IM; Schalken JA
Prostate; 2014 Sep; 74(12):1222-30. PubMed ID: 25043536
[TBL] [Abstract][Full Text] [Related]
6. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
9. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
12. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
13. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
[TBL] [Abstract][Full Text] [Related]
15. ERG induces taxane resistance in castration-resistant prostate cancer.
Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
[TBL] [Abstract][Full Text] [Related]
16. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
17. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D
Eur J Cancer; 2017 Dec; 87():30-37. PubMed ID: 29102858
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
